| Issue Date | Title | Author(s) |
| 2021 | Advancements in 3D Cell Culture Systems for Personalizing Anti-Cancer Therapies. | Law, AMK; Rodriguez de la Fuente, L; Grundy, TJ; Fang, G; Valdes-Mora, F; Gallego-Ortega, D |
| 2022-07 | ALTEN: A High-Fidelity Primary Tissue-Engineering Platform to Assess Cellular Responses Ex Vivo. | Law, AMK; Chen, J; Colino-Sanguino, Y; Fuente, LRDL; Fang, G; Grimes, SM; Lu, H; Huang, RJ; Boyle, ST; Venhuizen, J; Castillo, L; Tavakoli, J; Skhinas, JN; Millar, EKA; Beretov, J; Rossello, FJ; Tipper, JL; Ormandy, CJ; Samuel, MS; Cox, TR; Martelotto, L; Jin, D; Valdes-Mora, F; Ji, HP; Gallego-Ortega, D |
| 2013-09 | BCL-2 hypermethylation is a potential biomarker of sensitivity to antimitotic chemotherapy in endocrine-resistant breast cancer. | Stone, A; Cowley, MJ; Valdes-Mora, F; McCloy, RA; Sergio, CM; Gallego-Ortega, D; Caldon, CE; Ormandy, CJ; Biankin, AV; Gee, JMW; Nicholson, RI; Print, CG; Clark, SJ; Musgrove, EA |
| 2019-01-01 | Droplet-based single cell RNAseq tools: A practical guide | Salomon, R; Kaczorowski, D; Valdes-Mora, F; Nordon, RE; Neild, A; Farbehi, N; Bartonicek, N; Gallego-Ortega, D |
| 2015-12 | ELF5 Drives Lung Metastasis in Luminal Breast Cancer through Recruitment of Gr1+ CD11b+ Myeloid-Derived Suppressor Cells. | Gallego-Ortega, D; Ledger, A; Roden, DL; Law, AMK; Magenau, A; Kikhtyak, Z; Cho, C; Allerdice, SL; Lee, HJ; Valdes-Mora, F; Herrmann, D; Salomon, R; Young, AIJ; Lee, BY; Sergio, CM; Kaplan, W; Piggin, C; Conway, JRW; Rabinovich, B; Millar, EKA; Oakes, SR; Chtanova, T; Swarbrick, A; Naylor, MJ; O'Toole, S; Green, AR; Timpson, P; Gee, JMW; Ellis, IO; Clark, SJ; Ormandy, CJ |
| 2020-10 | Genomic Cytometry and New Modalities for Deep Single-Cell Interrogation. | Salomon, R; Martelotto, L; Valdes-Mora, F; Gallego-Ortega, D |
| 2020-02-27 | Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer. | Law, AMK; Valdes-Mora, F; Gallego-Ortega, D |
| 2023-07-19 | OPERA-gSAM: Big Data Processing Framework for UMI Sequencing at High Scalability and Efficiency | Caderno, PV; Awaysheh, FM; Colino-Sanguino, Y; Fuente, LRDL; Valdes-Mora, F; Cabaleiro, JC; Pena, TF; Gallego-Ortega, D; Simmhan, Y; Altintas, I; Varbanescu, AL; Balaji, P; Prasad, AS; Carnevale, L |
| 2023-05-01 | Pleiotrophin drives a prometastatic immune niche in breast cancer. | Ganguly, D; Schmidt, MO; Coleman, M; Ngo, T-VC; Sorrelle, N; Dominguez, ATA; Murimwa, GZ; Toombs, JE; Lewis, C; Fang, YV; Valdes-Mora, F; Gallego-Ortega, D; Wellstein, A; Brekken, RA |
| 2018 | Single-Cell Transcriptomics in Cancer Immunobiology: The Future of Precision Oncology. | Valdes-Mora, F; Handler, K; Law, AMK; Salomon, R; Oakes, SR; Ormandy, CJ; Gallego-Ortega, D |
| 2021-12-17 | Tumor dissociation of highly viable cell suspensions for single-cell omic analyses in mouse models of breast cancer. | Rodriguez de la Fuente, L; Law, AMK; Gallego-Ortega, D; Valdes-Mora, F |
